Bio Gin to Dismantle Its Global Sales Infrastructure for the Alsimers Drug

5min Snip

00:00

Play full episode

Summary

Transcript

Episode notes

Bio gin said yesterday it'll replace its ceo, michel vunaos. The company will dismantle its global sales infrastructure for the altheimer drug that was supposed to be a block buster but ended up a disaster. Tiger globel's flagship hedge fund is now down forty % this year. And some hedge funds that have invested in tech stocks are getting pummelled.

BP recorded its highest quarterly earnings in more than a decade, Italy’s prime minister, Mario Draghi, called on Brussels to abandon the requirement for unanimity on foreign policy decisions, and Biogen’s chief executive will step down following the disastrous launch of the company’s Alzheimer’s drug.

Subscribe to the FT News Briefing on Apple Podcasts or Spotify

Mentioned in this podcast:

BP’s bumper earnings stoke new calls for windfall tax

Mario Draghi calls for an end to EU unanimity on foreign policy decisions

Biogen chief steps down after Alzheimer’s drug flops

Tiger Global slumps more than 40% in first four months of 2022

The FT News Briefing is produced by Fiona Symon and Marc Filippino. The show’s editor is Jess Smith. Additional help by Peter Barber, Michael Lello, David da Silva, and Gavin Kallmann. The show’s theme song is by Metaphor Music. Topher Forhecz is the FT’s executive producer. The FT’s global head of audio is Cheryl Brumley.

Read a transcript of this episode on FT.com

Hosted on Acast. See acast.com/privacy for more information.